US 12,012,390 B2
Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease
Song Feng, Shanghai (CN); Chungen Liang, Shanghai (CN); Yongfu Liu, Shanghai (CN); Hong Shen, Shanghai (CN); Xuefei Tan, Shanghai (CN); Jun Wu, Basel (CN); Dongdong Chen, Shanghai (CN); Chao Li, Shanghai (CN); and Li Wang, Shanghai (CN)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Appl. No. 17/275,502
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
PCT Filed Sep. 11, 2019, PCT No. PCT/EP2019/074173
§ 371(c)(1), (2) Date Mar. 11, 2021,
PCT Pub. No. WO2020/053249, PCT Pub. Date Mar. 19, 2020.
Claims priority of application No. PCT/EP2018/074851 (WO), filed on Sep. 14, 2018.
Prior Publication US 2022/0363657 A1, Nov. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 311/30 (2006.01); A61P 31/20 (2006.01); C07D 335/06 (2006.01); C07D 405/04 (2006.01)
CPC C07D 311/30 (2013.01) [A61P 31/20 (2018.01); C07D 335/06 (2013.01); C07D 405/04 (2013.01)] 19 Claims
 
1. A compound of formula (I)

OG Complex Work Unit Chemistry
wherein:
W is O or S;
A1 is CH or CR4;
A2 is CH or CR4;
A3 is CH or CR4;
A4 is N, CH or CR4;
A5 is N, CH or CR4;
A6 is CH;
A7 is N or CH;
R1 is halogen, C1-6alkyl or C3-7cycloalkyl;
R2 is H, OH, halogen, C1-6alkoxy, haloC1-6alkoxy or phenylC1-6alkoxy;
R3 is carboxy or C1-6alkoxycarbonyl;
R4 is halogen, OH, CN, C1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, oxopyrrolidinyl, morpholinyl or haloC1-6alkyl;
G1 is C1-6alkylenyl, hydroxyC1-6alkylenyl or C3-7cycloalkylC1-6alkylenyl; and
G2 is C1-6alkylenyl, C3-7cycloalkylenyl or phenylene;
or a pharmaceutically acceptable salt, or enantiomer, or diastereomer thereof.